TACSTD2 and prostate neoplasm: This results suggests that the apparent dependency of androgen-sensitive cells upon TROP2 to improve recovery from cytotoxic treatment may be lost during progression towards the androgen-independent stage, at which point prostate tumors are reported to be more aggressive and chemotherapies such as docetaxel are known to be poorly effective overall [3].